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Primary immune deficiencies (PIDs) are a growing group of over 230 different disorders
caused by ineffective, absent or an increasing number of gain of function mutations in
immune components, mainly cells and proteins. Once recognized, these rare disorders
are treatable and in some cases curable. Otherwise untreated PIDs are often chronic,
serious, or even fatal. The diagnosis of PIDs can be difficult due to lack of awareness or
facilities for diagnosis, and management of PIDs is complex.This document was prepared
by a worldwide multi-disciplinary team of specialists; it aims to set out comprehensive
principles of care for PIDs. These include the role of specialized centers, the importance
of registries, the need for multinational research, the role of patient organizations, man-
agement and treatment options, the requirement for sustained access to all treatments
including immunoglobulin therapies and hematopoietic stem cell transplantation, impor-
tant considerations for developing countries and suggestions for implementation. A range
of healthcare policies and services have to be put into place by government agencies and
healthcare providers, to ensure that PID patients worldwide have access to appropriate
and sustainable medical and support services.
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INTRODUCTION
WHY A PRINCIPLES OF CARE DOCUMENT/CALL TO ACTION
Primary immune deficiencies (PIDs) are a large and growing group
of over 230 different disorders, caused when some components
of the immune system (mainly cells and proteins) are defective.
While PIDs are generally recognized as rare disorders, some are
more common than others. Taken as a whole, they represent an
important group of conditions that, if not treated, can be chronic,
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life-long, serious, and even fatal. The lives of patients with PIDs
are profoundly impacted by their condition. The immune system
normally helps the body to fight infections caused by germs (or
“micro-organisms”) such as bacteria, viruses, fungi, and proto-
zoa. Owing to defective immune systems, people with PIDs are
more prone to infections. In addition, a poorly regulated immune
system may start to attack tissues, leading to inflammation, and
autoimmunity (1, 2). When PIDs are left undiagnosed or are
misdiagnosed, chronic illness and disability take a heavy toll on
healthcare resources (3, 4).
The immune system is divided into two parts, each of which
contains two components: on the one hand, soluble proteins may
be particular for one germ (antibodies) or non-specific (comple-
ment). The other components are cellular – those that are specific
for one germ only (lymphocytes) and innate cells that are involved
in clearing all types of infections (such as phagocytes including
macrophages and neutrophils).
Primary immune deficiencies are currently classified into
groups, depending on the part(s) of the immune system affected.
Over half the affected patients have antibody deficiencies and their
treatment consists of replacing the missing antibodies (5). Cellu-
lar defects of lymphocytes are more severe and require replace-
ment of stem cells that can mature to effective immune blood
cells [hematopoietic stem cell transplantation (HSCT)] (6, 7) or
replacement of the faulty gene.
While it is considered that many PIDs can be diagnosed easily
with two simple blood tests (8), unfortunately many PIDs remain
undiagnosed due to failure to consider this diagnosis. In addition,
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access to treatment varies widely between different regions of the
world (9) and even from country to country within the same
continent.
In order to tackle these disparities and ensure early diagnosis
and appropriate access to treatments for all PID patients world-
wide, a range of healthcare policies and services need to be put
into place. While some countries have managed to do this, most
have not.
A worldwide multi-disciplinary team of specialists prepared
this document, which sets out comprehensive principles of care
for PIDs. These include the role of specialized centers, the impor-
tance of registries, the need for multinational research, the role
of patient organizations, the need for sustained access to all
treatments, including immunoglobulin (Ig) therapies and HSCT,
worldwide.
It is hoped that these principles of care will guide stakehold-
ers and decision-makers in a common goal to ensure that all PID
patients can access the care they are entitled to in order to live
normal and productive lives. There are examples of national and
international networks in other rare diseases that provide oppor-
tunities for collaborations to improve patient care, an example
being hemophilia. Such networks are fruitful and although already
underway in some areas, provision of sustainable infra-structures
is important to overcome major obstacles in the care of PID
patients throughout the world.
BRIEF PIDs OVERVIEW: RARE AND CHRONIC
Primary immune deficiencies are rare diseases of relatively recent
description. Infections were a common cause of death in the gen-
eral population up to the first half of the nineteenth century, so
these diseases were not suspected. With the advent of improved
hygiene and the development of vaccines and antibiotic therapies,
physicians began to realize that not all people with infections died,
and with increased life span, those with recurrent infections were
recognized.
In the second half of the twentieth century, the occurrence
of unusual (opportunistic) infections led to the understanding
of individual susceptibility to infection. Furthermore, increased
susceptibility seemed to occur in some members of a given
family, but not in others. Hence, the realization that in some
instances, susceptibility was inherited and this led to the dis-
covery that defects in immune mechanisms resulted in patholo-
gies known as PIDs. However, the effective action of antibiotics
can also “mask” the recognition of PIDs. When an infection
occurs and resolves, not all doctors will suspect a PID. So many
patients have a long history of infections before a PID diagnosis is
made and chronic sequelae have already developed (bronchiecta-
sis, malabsorption, etc.). Since PIDs are chronic diseases, once
recognised, patients require specific care for the rest of their
lives.
NEED FOR AWARENESS: ROLE OF KEY STAKEHOLDERS
Greater awareness is key to ensure PID patients can be diag-
nosed, treated, and lead productive lives all over the world. Target
groups include the public, patient, and healthcare professionals,
especially primary care physicians and specialists to whom PID
patients may present – see Section “Support for PID Diagnosis
and Complications in Other Medical Specialties.” Whilst aware-
ness of PIDs has been increasing dramatically in certain regions
of the world, the fact is that today a large majority of PID
patients remain undiagnosed and do not have access to appropriate
treatment.
Increasing awareness is of utmost importance to ensure that
the principles of care set out in this paper can be implemented as
widely as possible. The nature of awareness campaigns will vary
depending on the country. In many developing countries, greater
medical awareness is needed; political and financial factors play a
key role in educational efforts aimed at the medical and nursing
communities, which are crucial to ensure the first steps are taken
to improve the situation (10).
Awareness of the public is also important. In 2010, a world-
wide awareness campaign was created with the launch of World
Primary Immunodeficiencies Week (WPIW), which seeks to drive
such awareness. Patient organizations have been working tirelessly
on awareness campaigns to inform and educate the general pub-
lic, health policymakers and decision makers, schools and families
about PIDs in order to improve diagnosis rates and optimize access
to treatment.
IMPORTANCE OF ACCESS TO EARLY DIAGNOSIS AND SPECIALIST CARE
Access to specialist care is a problem in many countries. Diagnosis
of PIDs is often delayed, resulting in unnecessary complications,
and appropriate management is suboptimal or even unavailable,
especially in less developed regions. Access to early diagnosis and
specialist care ensures the best health outcomes not only for the
individual but also for society.
Early diagnosis shortens diagnostic delay that is distressing
to the family, damaging to the patient and wasteful of health-
care resources (11). Before the diagnosis is made, an individual
suffering from recurrent bouts of infections, autoimmune, or
inflammatory disease due to PIDs is often investigated by many
different specialists but without appropriate treatment or man-
agement. The end result is deterioration of the patient’s condition,
inappropriate use of health resources, and a feeling of helplessness
among all parties. The data resulting from a new service to over
1,000 suspected PID patients in Asia showed that families often
lost one or more children from an undiagnosed PID before the
current child was diagnosed (Pamela Lee, personal communica-
tion). Precise diagnosis can lead not only to specialist care for the
patient but also to genetic counseling/prenatal diagnosis for future
children.
Unfortunately, PID specialist care is often absent in less devel-
oped regions, even once an accurate diagnosis of PID is made.
Many governments, even in fast-growing economies, do not fund
life-long Ig replacement or HSCT, though both therapies are
effective and lifesaving. HSCT is a one-off curative treatment
for patients with several PIDs. Hence, access to early diagnosis
must be coupled with access to specialist care, to ensure appro-
priate therapy. This is a financial, and initially also a technical,
challenge for many countries, which require at least tempo-
rary international collaborations to provide the necessary treat-
ment, especially for HSCT. Therefore governments should rec-
ognize established reference centers and work in collaboration
with them.
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Table 1 | Criteria for fast and reliable PID diagnoses.
1. Early recognition of clinical manifestations suggestive of a PID before
serious complications compromise the patient’s health
2. High-profile medical awareness of PIDs and information campaigns for
referral of the patient
3. Consensus on basic screening tests, available to all primary health care
and hospital doctors (i.e., complete blood count and differential;
quantification of serum Ig levels)
4. Immediate access to a PID specialist for confirmation of diagnosis and
speedy treatment
5. Standardization of immunological diagnostic protocols
(immunophenotypes, protein analyses, in vivo and in vitro functional
tests) and validation of clinical and laboratory biomarkers for predicting
complications
6. Access to genetic counseling for the patient’s family after diagnosis
PRINCIPLE 1: THE ROLE FOR SPECIALIZED CENTERS
DIAGNOSTIC FACILITIES
Patient diagnoses
Although it is estimated that about 70% of PID patients are
undiagnosed, even in countries with existing PID facilities, it is
impossible to know (12). Prompt PID diagnosis results in better
use of health facilities (13) and has been demonstrated to result in
lower healthcare costs overall (14).
Criteria for fast and reliable PID diagnoses are given in Table 1.
Several multi-stage diagnostic protocols are available, according to
the clinical presentation that will optimize speed of diagnosis and
referral for therapy (2, 15).
Newborn screening
Severe combined immune deficiency (SCID) is a rare group of
disorders and is characterized by inadequate T lymphocyte pro-
duction or severe abnormalities of function (16). SCID is fatal
due to overwhelming infection(s) in the first year of life unless
definitive treatment with stem cells from a healthy donor’s bone
marrow or blood or gene therapy can be used to correct the under-
lying immune defect. In most cases, infants already have serious
infections at diagnosis; if these do not respond to standard treat-
ments, the infants die before immune reconstitution can even be
established. The key to improving the outcome for SCID is early
diagnosis and treatment, so that severe infections can be prevented
(17, 18). This significantly improves HSCT results, with an over-
all survival rate above 90% in those infants diagnosed at birth
due to a positive family history of SCID, compared to 40% in
cases diagnosed later because of serious infection or significant
complications (7). Diagnosis at birth means that babies can be
both protected from infection and transplanted earlier in a better
clinical state, all of which improves the chances of survival.
Newborn screening for SCID and other conditions with very
low T-cell numbers can now be performed by detecting markers of
healthy T-cell development in DNA extracted from the dried blood
spots already routinely obtained from infants by a simple heel
prick in the first few days of life (19). Results from recently estab-
lished programs demonstrate that newborn screening dramatically
Table 2 | Criteria for regional specialist PID centers for adults/children.
• Meet professionally defined minimum standards for PID diagnostic and
treatment services
• Provide specialist diagnostic and management services for patients
within an appropriate catchment area and to be accessible to this
population
• Provision of HSCT for children nationally and internationally
• Have effective patient engagement and monitor the patient experience
regularly to inform improvement in practice
• Ensure effective integrated care with primary and secondary healthcare
services, in particular, integrating with other hospital specialties
(seeTable 3)
• Commit to training and professional development for sustainability
• Contribute to national and thence international PID patient registries
(see National Registries)
• Undertake PID research
• Contribute to organization/lead the local/national network
• Undertake primary responsibility for clinical and observational trials
in PIDs
improves the outcomes of infants with SCID (20–22) and should
be implemented widely, not least as it is cost-effective.
SPECIALIST CENTERS AND NETWORKS FOR PATIENT MANAGEMENT
Patients with PIDs should be managed in regional specialist PID
centers (see Table 2) to enable equitable geographical access to
medical and nursing expertise in these diseases. Formal links
should exist between these regional immunology centers, with
recognized referral pathways for treatments. National centers in
different countries will vary depending on geography, available
resources and expertise but all should reach internationally agreed
standards of care, as in other rare diseases (23).
A national professional network raises standards of care
through dissemination of guidelines, registration, and peer review
of PID centers, patient registries, and professional leadership in
PID (24). Established professional networks, for which there are
different models in different countries, could be adopted as the
basis for provision of PID management by national healthcare
providers, whether governmental or insurance companies.
SUPPORT FOR PID DIAGNOSIS AND COMPLICATIONS IN OTHER
MEDICAL SPECIALTIES
The immune system is distributed throughout the entire
body. Accordingly, disturbances of immune function will have
repercussions on all other organ systems and patients may present
to a variety of medical and pediatric specialists. In addition, clini-
cal immunologists (adult and pediatric) cannot have the necessary
expertise to manage all potential medical and social complications
and must therefore have access to a broad range of supporting spe-
cialist services, with which they have good working relationships
and mutual understanding of the problems that are particular to
PID patients. The importance of access to biopsy services and
microbiological investigations cannot be over emphasized in all
specialties. These services (listed in Table 3) should ideally be in
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Table 3 | Key disciplines related to PID services.
• High-quality laboratory diagnostic services including for the investigation
of suspected PIDs
• Access to named histopathologists familiar with lymphoid and infectious
pathologies in PIDs
• Radiology services providing HR-CT, MRI, and PET scanning
• Intensive care services for management of overwhelming sepsis,
unstable pediatric/adult patients after HSCT, and life-threatening
complications
• Infectious diseases, to assist with the diagnosis and management of
unusual complex infections
• Respiratory medicine, to diagnose and advise in the management of
bronchiectasis and interstitial lung diseases
• Clinical hematology and hematological oncology, to undertake diagnostic
bone marrow examination; to manage severe cytopenias, stem cell
transplantation in children and adults, lymphoma and leukemia treatment
• Gastroenterology (adult and pediatric), for the management of
malabsorption, bowel infection, and other recognized complications
(autoimmune/inflammatory bowel disorders). This must include
endoscopy facilities and dietician support
• Hepatology, to diagnose and treat recognized hepatic complications;
this may include consideration of liver transplantation
• Dermatology, to diagnose autoimmune and infective skin conditions
particular to PIDs
• Clinical genetics, to help diagnose complex PID syndromes and to
counsel affected families
• Other tertiary services may also be needed, for example,
otorhinolaryngology (ENT), ophthalmology, neurology, and neurosurgery,
as well as social services and psychiatric support
• All services should participate in clinical audit of their involvement of PID
services
the same institution, to facilitate consultation and be accredited to
appropriate national/international standards.
ADOLESCENT CARE
Transition from adolescence to adulthood is characterized by
changes of many kinds: physical, social, psychological, educational,
and domestic (25). Coping with a chronic condition as well can
make adolescence more complicated.
Pediatric patients are usually treated from an early age by the
same staff, making it more difficult for the parent or patient to trust
new faces. Without a defined and coordinated pathway guiding
them toward adult services, the adolescent patient can become lost
to the system, leading to poor compliance with treatment, poten-
tial irreversible organ damage, lower life expectancy, and reduced
quality of life, all of which have health and cost implications.
As in other chronic diseases, planned transitional care for PID
patients is often overlooked but is a cost-effective way of prevent-
ing poor compliance resulting in further damage. It is vital to
ensure easy access to essential healthcare and support during this
period.
ROLE OF NEW GENETICS
There are currently over 230 genes that, when mutated are known
to disrupt immune function, and so cause a PID. This list is rapidly
expanding with the detection of more genes that are proving to
be important in explaining disorders of immune regulation and
autoimmunity as well as defects of infection protection.
Recent advances in genetic technology have helped immensely
in the diagnosis of PIDs. These include traditional sequencing
of specific genes (particularly in families for genetic counseling),
whole exome (and soon whole genome) sequencing (both with
appropriate bioinformatics for interpretation) and chromosomal
microarrays (detailing which parts of the genome are missing
or duplicated). Another important area of investigation is the
“mutational load” of genetic lesions causing PIDs, which is the
combined impact of mutated genes, and copy number variations,
which cause missing or duplicated parts of genes or entire genes
(26). The latter has been especially relevant in common variable
immunodeficiency disorders (CVID) (27), the commonest form
of symptomatic PID. Future studies will likely show that regula-
tory regions of DNA are also important for expression of immune
system genes and changes involving genes during life – epige-
netics – may also be involved. Activating mutations can cause
PIDs and somatic mutations may require analysis of DNA from
particular cell populations to establish a diagnosis.
These technologies are already available in some centers and
will be increasingly used in patient care in all medical specialties.
As costs tumble and access to these technologies becomes more
widespread, a combination of techniques will be used to diagnose
previously unknown PIDs as well as provide earlier detection, with
prognostic, therapeutic, and genetic counseling benefits.
PRINCIPLE 2: THE IMPORTANCE OF REGISTRIES
NATIONAL REGISTRIES
Primary immune deficiencies are recognized as rare conditions
and data on epidemiology of PIDs is scarce, although many coun-
tries across the EU and worldwide have implemented registries for
PIDs. An example is that established in France in 2005; the Ref-
erence Center for PIDs (CEREDIH) (28) runs the largest national
PID registry worldwide, with dedicated and highly trained staff.
It is based on a tight network of all university teaching hos-
pitals, with 130 clinicians and at least 30 diagnostic immunol-
ogy laboratories (29). National registries are important tools
for assessing the proportion of affected individuals among the
general population (prevalence) as well as measuring the num-
ber of new cases diagnosed each year (incidence), detection of
areas of low-diagnostic rates and provision of insights on diag-
nostic delay associated with increased morbidity and mortality.
A registry also provides information that is helpful to govern-
ments regarding estimates of those not diagnosed, to aid planning
of educational programs and provision of treatments and their
costs. Presentation of this data to pharmaceutical industries helps
to ensure that the supply of relevant medical products meets
demand.
Thus, a national registry is an important tool for health policy
makers, stakeholders, and health insurers, enabling plans for allo-
cation of therapies and the development of innovative treatments,
as also demonstrated in the UK Demand Management Plan (30).
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INTERNATIONAL EXPERIENCE OF REGISTRIES
Studies on PIDs require international collaboration. Even in large
individual European countries, no more than six to eight new
patients with particularly rare genetic variants of PIDs are diag-
nosed per year. To collect information on all PIDs including the
very uncommon cases, the European Society for Immune Defi-
ciencies (ESID) set up an initial registry in 1994 in Sweden,
supplemented by an online database in 2004. In the last 2 years,
the ESID registry has been completely revised in order to pro-
vide information for national registries, healthcare providers and
the European Commission. Evaluation of large registry data also
provides information for individual physicians, with limited per-
sonal experience of PIDs, to answer pressing questions relating to
patients or families (31).
Other continents have followed with the formation of con-
tinental registries by the Latin American Society for Immune
Deficiencies (LASID) and more recently the African Society for
Immune Deficiencies (ASID), and others are planned. These reg-
istries also have a role in raising awareness in countries in which
the only immunodeficiency receiving attention from healthcare
providers and the general public is HIV – a totally unrelated
condition.
The United States Immune Deficiency Network (USIDNET), a
program of the Immune Deficiency Foundation (IDF), was cre-
ated in 2003 for patients in Canada and the US. The aim was to
solicit, develop, evaluate, and implement clinical research strate-
gies to advance detection, understanding, diagnosis, and treatment
of PIDs. The USIDNET registry records patient data to provide
both support for retrospective research studies and a source of
help to physicians in making clinical decisions. USIDNET is also
utilized by patients seeking information on PIDs and engages them
holistically (32, 33).
International registries also provide information to centers in
developing countries in which there are no national networks
as yet.
PRINCIPLE 3: THE NEED FOR INTERNATIONAL
COLLABORATIONS FOR SCIENTIFIC RESEARCH
International collaboration is not only important for diagnosis
(genetics) and treatment (HSCT) of patients but also for research.
Clinical research on PIDs faces a range of difficulties, because of
scarcity of these diseases. International collaboration is necessary
in order to collect sufficient patient numbers for adequate clini-
cal research, as well as to develop new diagnostic and therapeutic
strategies, for epidemiologic studies and the identification of novel
disease-associated genes (34). PID disorders are caused by a large
variety of genetic defects, and not all monogenetic defects have
been discovered, to date, let alone those that are oligogenic or
disease modifying genes. Worldwide networks, such as the JMF
Network (35), need to be encouraged and developed in all coun-
tries and continents in which these support facilities do not yet
exist. It is important to note that the EU, among others, has cre-
ated special programs for rare diseases (23), which help to fund
the necessary financial coverage for this type of research. The
International Rare Diseases Research Consortium (36) provide
general guidelines for diagnostic investigations, encouragement
for drug/treatment development, visibility for funding calls, and
publication of new results.
PRINCIPLE 4: THE ROLE OF PATIENT GROUPS
Patient organizations have a significant role to play in health-
care systems and are increasingly key stakeholders in the political
decision-making processes in healthcare. Today, it is well recog-
nized that patient representatives have become true experts in
their conditions and relevant treatments, and can bring unique
and personal perspectives on the impact of diagnosis and treat-
ment to their communities. All countries should aim to have
an efficient national patient organization, representing all PID
patients – children and adults – in order to give them a voice
and represent their interest in policymaking. Effective national
patient organizations provide advice, education, and support to
patients and families and their healthcare providers too. They
have a pivotal role to play in ensuring that their community
is kept informed and updated about latest developments in a
wide range of areas including medical and scientific advances,
political and regulatory decisions, supply and safety of life-saving
treatments.
Patient groups are increasingly active in collecting clinical data
and participating in the management of registries, which yield
important useful information and help to guide decisions affect-
ing their health. They are also the driving force behind awareness
campaigns around the world. To do this successfully, collaboration
with doctors and other key stakeholders such as nurses, regulators,
civil servants, decision makers, and industry is of vital importance,
as many voices resonate louder than one. Patient-centered policies
improve compliance, and therefore outcomes, once the interest of
the patient is at the center of the decision making process.
At the international level, organizations such as the Inter-
national Patient Organisation for Primary Immunodeficiencies
(IPOPI) (37) have 51 national patient member organizations so
far (38) and are actively involved in assisting new countries to start
such an organization. They are involved on many different fronts,
providing the patients’ expertise in international committees and
institutions, including making representations to the European
institutions and the World Health Organization.
PRINCIPLE 5: MANAGEMENT AND TREATMENT OPTIONS
FOR PIDs
NATURE OF Ig REPLACEMENT THERAPIES
There are several types or “classes” of human Ig in blood; these
include IgG, IgA, and IgM. Among these, IgG has the highest con-
centration in blood and body fluids and is critical for protection
against infection. IgG is purified safely from human plasma and
administered to people who are unable to produce a sufficient
amount of good quality of IgG themselves, as a result of PID.
Such IgG replacement treatment is literally life saving for such
individuals and usually needs to be continued for life.
The IgG products used for replacement therapy are protective
against a broad range of infections. This explains why therapeutic
Ig cannot be made by recombinant technology, as for other drugs.
Ig therapy is also distinct from “monoclonal antibodies” that have
recently been developed to treat specific diseases rather than to
protect from all types of infections.
Immunoglobulin replacement therapy is absolutely essential
for the treatment of the majority of patients with a PID. There
are a variety of IgG products currently marketed worldwide (39).
Each new product undergoes clinical trials to establish efficacy
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(protection from infection), safety (no disease transmission or
seriously harmful adverse events), and tolerability (minimal side
effects) before it can be sold.
Although Ig therapies have been in clinical practice for over
60 years, there are still challenges since Ig products are not yet
available to all PID patients (Table 4).
Safety of immunoglobulin therapies
Immunoglobulin products are prepared from plasma collected
from tens of thousands of screened blood/plasma donors under
carefully controlled conditions and thus contain a vast repertoire
of neutralizing antibodies to defend the recipient against the range
of pathogens. Each company uses slightly different proprietary
methods to purify IgG molecules to a high degree (typically>98%)
and to reduce the possibility of disease transmission. All available
products have been shown to protect against infections.
Over the last 50 years, purification and manufacturing methods
have improved tremendously. There have been no known cases of
disease transmission by therapeutic Ig in the past 20 years. Since
1994, viral safety has been robust, due to specific genetic test-
ing of individual donations and implementation of a number of
viral inactivation/removal steps. Authorized products contain at
least two viral inactivation/removal steps. To date, there has been
no known transmission of pathological prions (the agent causing
variant Creutzfeldt–Jakob-disease) with Ig.
Most PID patients are able to receive Ig replacement therapy
without side effects at all. A few patients may need some medi-
cines (non-steroidal anti-inflammatory drugs and antihistamines)
to treat mild side effects. A very few (1%) may have more trouble-
some side effects, but serious reactions are very rare indeed. With
the variety of products and infusion options available, almost all
patients can be treated successfully with Ig. However, it is impor-
tant to realize that there is no single Ig product or method of
administration that is suitable for all PID patients.
All blood products carry an infection risk, and like others,
Ig products are regulated by national or international regulatory
bodies to be sure that they are safe and of high quality. These bodies
share their information worldwide. Excipients, preservatives, pH,
IgA content, and protein concentration vary between Ig products
and thus alter the side-effect profiles; respective warnings are stated
in the product specific labeling. Constant vigilance is necessary to
detect any new clusters of side effects of Ig therapy that may result
from changes in manufacturing, concentration of the product,
infusion rates, or expansion to new indications. Recent examples
of investigations following unexpected side effects include the risk
of thrombotic events and hemolytic episodes.
Optimal treatment levels of Ig replacement therapy
The key principle goal of Ig replacement therapy is to prevent
bacterial infections and avoid organ damage that leads to chronic
disease and poor quality of life. Infection prevention rather than
a targeted serum IgG level is the goal of Ig replacement therapy as
the protective serum IgG level varies with individual patients (40).
In a meta-analysis of 17 clinical trials, there was a 27% decrease in
the incidence of pneumonia for every 100 mg/kg/28 days increase
in the dose of Ig therapy (41). Patients with chronic gut disease
or bronchiectasis require higher doses of Ig replacement therapy
Table 4 | Current challenges to Ig therapy.
• Provision of finances to ensure availability of several Ig products in every
country, to enable wide access to appropriate therapies, as per WHO
Essential Medicines Lists
• Early diagnosis to prevent infection-related complications such as
bronchiectasis
• Selection of optimal therapy and dosage for each patient, with regular
medical follow-up to check reduction/abolition of breakthrough infections
• Increasing doses with growth in children
• Expert treatment centers, with dedicated nursing staff, to avoid side
effects due to incorrect infusion techniques in first few infusions
• Training for self-infusion by suitable patients at home, with regular
follow-up to ensure on-going high standards
• PID patients are prioritized for Ig products in times of restriction (for
financial or availability reasons)
• Improvement of outcomes for complex patients by using additional
therapies for disease-related complications
(29). Other studies of patients with antibody deficiency receiv-
ing subcutaneous Ig replacement therapy show similar findings.
However, cost implications may prevent optimal doses being used
and it is important for patient groups and healthcare professionals
to unite to explain to healthcare providers the importance, both
medically and financially, of optimal dosing.
Replacement Ig therapy has been shown to be cost-effective
in preventing hospitalizations and emergency departments visits,
unscheduled physician visits, expensive antibiotic treatments and
missed days of school or work. These studies emphasize that the
appropriate dose of Ig replacement therapy enhances quality of
life measures too (42).
Access to a wide choice of Ig therapies
Human Ig preparations reflect the infectious or immunization
exposures of the plasma donors. However, due to patent law, they
cannot be considered as generic drugs (i.e., connected together
by the same chemical composition, pharmacological effects, treat-
ment use, and same adverse effects) as Ig production methods vary.
Therapeutic Ig is administered by three routes: subcutaneously
(SC), intravenously (IV), or intramuscularly, though the latter
is no longer recommended due to high rates of infusion related
reactions. SC and IV have specific advantages and disadvantages,
which may depend on the patient’s medical background or on per-
sonal preferences. Frequency of treatment, the availability of good
venous access and other factors all play a role and it is impossible
to say that one brand or route of administration is generally bet-
ter than another. Therefore, all countries and immunodeficiency
centers should have access to a wide spectrum of Ig products, to
provide optimal treatment for all immunodeficient patients.
Recognition of PIDs as priority indications for Ig therapy
Immunoglobulin replacement therapy for PIDs was primarily
developed for patients with antibody deficiencies in the last half
of the twentieth century. Since then many other indications in
autoimmunity or immune dysregulation have been recognized,
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resulting in much larger amounts of intravenous Ig being used
in these conditions, often in off label usage not recognized by
the regulatory authorities. For some autoimmune diseases, alter-
native therapies are available and monoclonal antibodies, such
as rituximab, may supersede the use of high dose Ig therapies in
autoimmunity in time. However, the available amount of Ig is lim-
ited, depending as it does on blood donors. Therefore, for now, Ig
therapy should be prioritized for PIDs since there are clear indica-
tions, proven efficacy, and no alternative treatments available. This
was the reason why Ig products were accepted to the WHO Lists
of Essential Medicines both for adults (43) and children (44).
SITE OF Ig TREATMENT (SPECIALIST CENTER, LOCAL HOSPITAL, HOME)
To replace missing antibodies, the antibody deficiency patients
need Ig on a regular basis for the duration of their lives. Although
initial treatments are started under supervision in a day care facil-
ity with experienced staff, once stable, patients can either self-treat
or be treated at the local hospital or health-care center. There still
needs to be regular contact with the specialist immunology nurses
and both easy access to and regular follow-up by the PID doc-
tor, since complications can occur later and significant damage
from infection or chronic inflammation, particularly for children
or adults who are diagnosed late, needs to be monitored. Research
has shown that self-infusions at home after education are effec-
tive, safe (45), and appreciated by patients and families, as this
results in less disruption to work and school as well as social lives
(Table 5) (31, 46). This is also appropriate for some children or
infants awaiting HSCT if a donor is difficult to find.
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Hematopoietic stem cell transplantation (from blood or bone mar-
row) is the only cure for severe, otherwise fatal PIDs that present
in infancy or early childhood and all SCID children should have
access to this life-saving therapy, regardless of where they live.
Bone marrow resides in the cavities of the long bones of the
body and contains stem cells for all the cellular components of
the blood. Stem cells are capable of repopulating a new immune
system throughout life, so some are present in blood as well and
can be purified following adult or cord blood donation.
The first bone marrow transplants were performed over
30 years ago but until recently were too risky to do in any but the
sickest patients. Today, progress has made HSCT feasible for an
increasing number of patients, though outcomes are determined
by a variety of factors (Table 6).
Tissue types are diverse around the world and statistically the
chances of finding a match are higher within one’s own ethnicity.
Donor recruitment strategies vary from country to country but
patients who come from under-represented ethnic backgrounds
can have a difficult time finding a “match.” Knowledge regarding
transplantation, cultural, and technical limitations can hamper
the broad recruitment needed to ensure that every patient who
requires it has access to this life-saving treatment.
Raising awareness of the success of HSCT and additional
research into outcomes is needed to continue the impressive suc-
cesses in this field. Optimal treatment to prepare the body for
the transplant has been studied for a decade, with tremendously
improved outcomes (6), yet children and adults still die due to the
Table 5 | Advantages of programs for self-infusion at home.
• Adult patients report that they are less tired, can plan their lives and do
not have to miss work to attend treatment sessions
• Parents report that home-therapy keeps the child healthier due to
regular treatment, enabling participation in school activities
• Participation in family/social and leisure activities for adults and playing
with friends for children allow them to feel and act like others
• Parents themselves report less worry for the future of their child, fewer
restrictions or sudden changes in plans in relation to family activities
(e.g., holiday trips), less tension at home and more time for own needs
and therefore have a higher quality of life
Table 6 | Current challenges to hematopoietic stem cell
transplantation.
• Identifying candidates before they sustain significant damage from
infection, particularly for children or adults diagnosed late
• Recruiting appropriate donors, since a “match” between donor and
patient is essential for a good outcome
• Improving the outcomes for the sickest patients with complex PIDs
depends on determining the involvement of other tissues or organs
risks of the process and patients require great stamina for the rig-
ors of maintaining ideal conditions. Gentler strategies are under
development and additional research may pave the way for our
goal of curing 100% of patients who need HSCT.
ADDITIONAL ANTIMICROBIAL MEASURES
Infection is the most common presentation, the nature of which
depends on the underlying immune defect. More than one infec-
tion may be present and more than one organ affected. Occult
infections require careful imaging, tissue sampling, and molec-
ular techniques needed to identify the pathogen. Treatment of
infection in PID patients is complex, often requiring one or more
broad-spectrum antimicrobials and for prolonged time-courses,
and physiotherapy is essential for those with lung complications.
If an innate PID is diagnosed for which there is no specific
effective therapy, prophylactic antimicrobials may be given. Phys-
ical barriers range from sterile positive pressure ventilation for
extremely immunodeficient infants to specific measures such as
boiling water or avoidance of exposure to fungi. Anti-bacterial
prophylaxis is used to prevent pneumococcal or meningococcal
disease in patients with complement deficiency or hyposplenism.
Treating existing fungal infections in patients with innate defi-
ciencies is a huge challenge, with larger doses of increasingly
toxic antifungal agents and even neutrophil transfusions as well
as surgical drainage.
IMMUNOLOGICAL AND OTHER TREATMENTS
Other replacement therapies or even immunosuppression to
counter the aberrant immune responses may be necessary. Exam-
ples include granulocyte-colony stimulating factor (G-CSF) to
boost the production of neutrophils or gamma interferon in
patients with defective neutrophils.
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Long acting adenosine deaminase (PEG-ADA), an enzyme
replacement therapy, is administered to patients who lack ADA
prior to HSCT.
Anti-inflammatory agents, such as corticosteroids, and
immunosuppressive agents are useful for particular complica-
tions (including respiratory, gastro-intestinal, and dermatologi-
cal). Nutritional supplements and other types of therapies (phys-
iotherapy, psychotherapy) are also used to treat PID patients with
specific complications.
This list of other treatments is not exhaustive but provides
examples of the complexity of therapies that should be available
to ensure appropriate care for all PID patients.
GENE THERAPY
A new approach to replacement of faulty genes has been developed
in recent years, though currently remains a research tool. Gene
therapy is defined as the addition of a normal copy of a gene to a
patient’s purified stem cells to supplement the one that is defec-
tive or absent. This is currently reserved for children for whom
HSCT is not available (generally because they do not have a suit-
able matched donor for HSCT). Successful clinical trials started in
Paris in 1999 for patients with X-linked SCID. More recently, these
have been extended at several centers to include patients with ADA
SCID, CGD, and Wiskott–Aldrich syndrome. Most of the patients
have been successfully treated and are at home, off all therapy, thus,
proving that such therapy is possible and effective (8).
However, there have been a small number of patients who devel-
oped leukemia-like disorders as a result of unwelcome mutations
in the cells as a result of using the original retroviral vectors – a
process known as insertional mutagenesis. New improved self-
inactivating retroviral and lentiviral vectors have been developed
incorporating additional safety features and these are now being
used in clinical trials in the same patient groups.
VACCINES
Vaccination – or more commonly – immunization is the admin-
istration of material derived from infectious material in order to
produce a protective immune response to a specific pathogen (bac-
teria or virus) without developing the infection. The material in the
vaccine can be modified (attenuated) or killed (inactivated) whole
micro-organisms, defined components of the microorganism or
specific proteins such as modified toxins (known as toxoids).
Those that consist of live-attenuated bacteria or virus can undergo
reversion to a more virulent form and cause disease (unlike the
killed micro-organisms). In general, attenuated vaccines includ-
ing BCG and rotavirus, must be avoided in all the severe forms
of PID (SCID, CGD, T-cell defects, etc.), as in such patients there
will be no protective immune response and therefore a clear risk
of developing the disease itself (47). If BCG is given in the first
month of life, infants with severe PIDs or MSMD develop gen-
eralized BCG-osis that compromises HSCT and is often fatal. To
postpone the age of BCG vaccine would prevent this (48). If BCG
administration cannot be delayed,newborn screening is important
to identify at-risk babies.
Inactivated vaccines are safe for use in most PID patients but
are ineffective if there is no or only a limited immune response,
depending on the type of immune failure. SCID patients are only
immunized after HSCT has restored a healthy immune system.
If the patient cannot produce antibodies, vaccines are ineffective
though patients may produce a T-cell response that will prevent
or lessen any subsequent, particularly viral, infection.
In those PIDs due to neutrophil defects, complement defi-
ciencies and some mild forms of antibody failure, vaccination is
beneficial (41) and forms part of the treatment protocol.
It is necessary to discuss the risks and benefits to the specific
individual with the patient’s pediatrician or specialist immunol-
ogist as well as the patient (49). Immunization of household
relatives to prevent close-contact infection, such in an influenza
outbreak or to provide on-going protection in a meningitis or
chickenpox outbreak, is helpful.
Killed vaccines are also used in diagnostic procedures if anti-
body failure is suspected; failure of specific antibody production
indicates an immune defect.
COMPREHENSIVE AND HOLISTIC APPROACH TO THE PATIENT
Primary immune deficiency patients encounter a diversity of clini-
cal manifestations during their lifetime (infections, autoimmunity,
granuloma, allergy, lymphoproliferative disorders, and malignan-
cies). Thus, expert management according to the best international
standard of care is warranted and acknowledgment of the personal
context of the patients. Treated patients now have an increased life
expectancy but there are new and unexpected complications seen
with longer life, as well as difficulties in transition to adolescence
and adulthood. Thought should be given to long-term care plans
and access to genetic counseling when patients consider having
children of their own. As their life progresses, modifications to
treatment will be needed to fit in with changing circumstances
such as work, studying, travel, or pregnancy. Patients need to have
assistance and choice in treatment modalities and to be able to
change the route, dose and location of Ig replacement (IVIgs versus
SCIgs and home versus clinic) especially as children grow.
Impacts on a patient’s life include stress, anxiety, chronic
fatigue, pain, disability, fertility, and psychosocial aspects. Advice
about sports to relieve complications such as bronchiectasis, safety
measures for traveling (including places where safe drinking water
is not easily available), avoidance of inappropriate hobbies, how to
obtain health insurance, etc., should be given by trained healthcare
professionals. Further studies are needed.
EMERGENCY MEDICINE
Primary immune deficiency patients may need emergency treat-
ment, so every patient should have an individually tailored plan
(medical diagnosis, specific therapy, expert center contact), out-
lining management of emergencies common to their immunod-
eficiency, and ensuring access to specialist medication. If direct
access to the specialist center is impractical (for example, because
of distance), shared care should be sought with local direct-access
staff who are informed in the care required. Emergency staff are
unlikely to be familiar with management of immunodeficiency
and the patient may be at-risk of delayed or inappropriate care;
a 24-h contact number for specialist advice must be included in
the patient’s plan. This is particularly important for patients with
complement deficiencies in whom the correct emergency therapy
undoubtedly saves lives.
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PRINCIPLE 6: MANAGING PID DIAGNOSIS AND CARE IN ALL
COUNTRIES
ACCESS TO PID CARE WORLD-WIDE
The broad scope of PID clinical presentations presents special chal-
lenges (Table 7), especially in developing countries lacking even
basic health care; infectious diseases are common and so PIDs are
missed. Yet, diseases that are rarer than PIDs still achieve good
diagnostic and treatment levels in low-income countries through
organized efforts.
In the context of high prevalence of infectious diseases in devel-
oping countries (in particular, infections resulting from HIV)
PIDs, which are due to intrinsic failure of the immune system,
are now more likely to be exposed.
ACCESS TO PID DIAGNOSIS
Diagnosis of PID is a challenge under any circumstances, but even
more so in a resource-constrained setting of developing coun-
tries. Clinicians must be sure to select scarce (often expensive)
laboratory resources judiciously to avoid an unnecessary work-up
in a suspected PID. Understanding the clinical clues (Table 8)
Table 7 | Integrated approaches for PIDs.
• Awareness for recognition and management of PIDs through clinician
education, training, and advocacy groups should be taken on, often in
association with those already experienced in PIDs
• Investigation and management of PIDs should be integrated into
resources allocated to the epidemics of malaria, HIV, tuberculosis, and
other locally prevalent diseases
• National organizations should be established to oversee the provision
of national specialist PID care centers, providing the entire spectrum of
clinical and laboratory services and supporting a network of smaller
centers
• International collaboration between established centers and less
experienced centers to guarantee access to optimal diagnostics and
possibly treatments, particularly in the case of HSCT
• A national registry for PID diagnoses must be established to provide
data to healthcare providers
and using a small set of basic tests enable diagnosis of most
PIDs enables appropriate treatment to be sought. As there are
few centers and few immunologists in developing countries, it is
important to set up a network, using the Internet, to discuss clin-
ical cases and support of physicians who live far from specialized
centers. International links are helpful too.
With this simplified approach, it is possible to diagnose the vast
majority of common PIDs (50).
ACCESS TO PID TREATMENTS
Best level of available PID care must be pursued, even if the full
range of treatment options is not available. Knowledge must be
promoted on treatment and prevention of infectious diseases with
hygiene measures, nutritional support, vaccines, and antibiotics.
Very often developing countries are specifically faced with impor-
tant challenges with regards to relatively expensive therapies used
in the treatment of PIDs, mostly because of cost constraints or a
lack of expertise.
Immunoglobulin therapies are listed as Essential Medicines
by the WHO (43, 44) and should be made available for PID
patients in all developing countries. While HSCT has been the
standard of care in developed countries for most forms of severe
PIDs, it is frequently not available in developing countries though
the situation is slowly improving. The cost of building appro-
priate facilities and of providing expert training locally may
seem significant but actually allows for more efficient manage-
ment of healthcare resources, as many SCID patients in devel-
oping regions currently have to travel to developed countries
where the cost is higher. International collaboration and the
creation of regional societies such as ESID in Europe, LASID
in Latin America, and ASID in Africa have been and will con-
tinue to be pivotal in increasing PID expertise in developing
countries.
IMPLEMENTATION
Vast gaps in knowledge of PIDs and translation of diagnosis and
management into clinical practice exist between regions,countries,
and even areas. This causes unnecessary suffering and deaths, par-
ticularly in developing countries. PID facilities should be at least
Table 8 | Clues toward a diagnosis of a PID.
History Physical examination Investigations
Failure to thrive Paucity of lymph nodes/tonsils Full blood count for neutropenia, lymphopenia, or
neutrophilia
Onset of serious infections, especially in infancy/early
childhood
Failure of obvious inflammation or
unexplained inflammation
Serum immunoglobulin levels – IgG, IgA,
IgM+/−IgE
Recurrent or unusually severe infections in adults May be enlarged spleen or liver Flow cytometry (to define blood immune cells)
Infections with an unusual or seemingly innocuous
(opportunistic) organisms
Huge lymphadenopathy Oxidative burst tests (for neutrophil function)
Chronic, non-infectious inflammation of unknown origin,
leading to severe or unusual organ damage
May be persistent rash or skin
infections
Microbiological examination of tissue, fluids, stool,
sputum, or alveolar washings; measure IgE
Family history of severe, persistent, unusual or recurrent
infections (SPUR)
Congenital defects in other
organs/systems
Imaging of affected organs
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as good as those for other, even rarer, diseases. Services for diag-
nosis and treatment can be developed initially alongside facilities
for diagnosis and monitoring of HIV patients or located with
immunization centers. In order for the best level of available PID
care to be pursued, even if the full range of treatment options
may not be available, knowledge of PIDs must be promoted, and
infra-structure for diagnosis and care implemented.
This involves, by stages:
• Raising awareness and understanding of the clinical clues among
local healthcare workers, general physicians, and pediatricians so
that patients are diagnosed quickly;
• Provision of inexpensive tests (often already available in district
hospitals/healthcare centers) plus guidance on their interpreta-
tion and indications for further complex testing;
• Defining practical pathways to obtain appropriate therapies for
the patient.
With this simplified approach, it is possible to diagnose and
treat the majority of common PIDs.
To achieve these aims, professional stakeholders in PIDs have
to come together in a network to:
• Share information informally regarding individual patients and
access to all relevant treatments including HSCT, and to make
this knowledge available to others;
• Agree to share relevant specialist investigations so that all useful
assays are available to patients throughout every country;
• Construct and publish a consensus document on the need for
and provision of PID services nationally (51) and use this to
persuade healthcare providers to establish regional and national
centers for complex investigations and therapies;
• Seek advice from established centers in other countries or
continents and to establish links for treatment, training, and
education with these centers;
• Meet at least annually and to correspond regularly or post
information and questions on a website;
• Include patient organizations, who are key stakeholders in
healthcare decisions and who can also assist with clinical data
collection.
Established professional networks should be recognized, for-
malized, and adopted as the basis for provision of PID manage-
ment by national healthcare providers, whether governmental or
insurance companies. Network responsibilities also include regis-
tration of patients (33), setting of national standards, and auditing
PID services to these standards (52).
As in the provision of other rare diseases, services for PID
patients usually involve recognized expert centers for complex
diagnostic facilities as well as experience in treatments, whether
Ig replacement or HSCT. In well-established countries, there may
be several expert centers, each concentrating on a particular type of
PID, with a broad range of supporting specialist services; this has
the advantage of concentrating resources for research. Good links
with pediatric services are essential for planned transitional care
and the importance of a national registry has been emphasized
above (53).
CONCLUSION
In conclusion, we call upon international and national health-
care policy makers to join us in taking strong and decisive action
to ensure that people with PIDs are diagnosed as early as possible
and have appropriate access to safe, efficient life-saving treatments,
and optimum care throughout the world.
We endorse the above principles, as elements of PID care pro-
vision that should be available and implemented in each country.
These include specialized centers, PID registries, provision for
transnational research, patient organizations, access to services
for diagnosis and treatment, the need for sustained access to
all treatments including Ig therapies and HSCT, and important
considerations for developing countries.
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